Education
About Us
Working with TipRanks
Follow Us
Upstream Bio, Inc. (UPB)
NASDAQ:UPB
UPB Stock Chart & Stats
$30.30
$0.36(1.20%)
At close: 4:00 PM EST
$30.30
$0.36(1.20%)
Day’s Range― - ―
52-Week Range$5.14 - $33.68
Previous CloseN/A
Volume30.66K
Average Volume (3M)388.50K
Market Cap
$416.10M
Enterprise Value$326.71M
Total Cash (Recent Filing)$372.43M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 18, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding54,038,590
10 Day Avg. Volume473,530
30 Day Avg. Volume388,499
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.80
Price to Sales (P/S)356.14
P/FCF Ratio-14.14
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue116.72
Enterprise Value/Gross Profit118.03
Enterprise Value/Ebitda-2.40
Forecast
1Y Price Target
$52.25Price Target Upside72.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.1
Revenue Forecast (FY)$1.54M
Bulls Say, Bears Say
Bulls Say
Efficacy Data Vs CompetitorPhase II results indicate efficacy comparable to the market-leading therapy on primary clinical measures, supporting the drug's potential to compete effectively if replicated in registrational studies.
Physician Prescribing IntentSurveys of high-volume allergy and pulmonology physicians show a large majority would be likely to prescribe the drug, signaling meaningful clinician interest that could drive uptake.
Safety And Broader Clinical BenefitNo notable safety or tolerability signals were observed and consistent improvements in lung function and inflammatory markers suggest broader patient benefit beyond the main endpoint.
Bears Say
Commercial Adoption HurdlesLow switching rates between biologic classes and high expectations for meaningful exacerbation reduction set a steep commercial bar that could limit market share gains.
Funding And Near-term Catalyst RiskNeed for additional capital to fund multiple confirmatory trials combined with a lack of imminent clinical catalysts increases financing risk and may pressure the stock.
Phase III Strategy UncertaintyAn undefined Phase III dosing strategy raises regulatory and clinical risk by leaving the optimal dose and approval pathway unclear for investors and regulators.
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $416.10M.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 14 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.782 by $0.152.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate is -0.7.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,038,590 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.782. Following the earnings report the stock price went down -1.293%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Upstream Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.25 (72.44% Upside)
$52.25 (72.44% Upside)
Hedge Fund Trend
Increased
By 141.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 12.7%
Last 30 Days ▲ 12.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.21%
12-Months-Change
Fundamentals
Return on Equity
-40.80%
Trailing 12-Months
Asset Growth
68.11%
Trailing 12-Months
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development of novel treatments for various diseases, particularly in the fields of oncology and autoimmune disorders. Upstream Bio aims to leverage its proprietary technology platform to advance its pipeline of drug candidates, ultimately seeking to improve patient outcomes through targeted therapies.
UPB Stock 12 Month Forecast
Average Price Target
$52.25
▲(72.44% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.76% Insiders
19.53% Mutual Funds
9.46% Other Institutional Investors
53.01% Public Companies and
Individual Investors